en
fi
Orion Group
Menu
Menu
suomeksi
Orion Now
Other websites
Fermion
Orion Pharma Animal Health
Wehale.life
Orion countries
Orion Group
About Orion
Products and services
Partnering and licensing
Investors
Media
Corporate Governance
Contact us
Careers at Orion
Open vacancies
Working at Orion
Students
Career stories
Research
Orion R&D
Research areas
Research for patient well-being
R&D pipeline
Scientific publications
Sustainability
Policies
Management of Sustainability
Sustainability Reports
Patient organisation collaboration
Stories about responsibility
Raising the Bar
Health Professionals
Simdax.com
Dexdor.eu
Wehale.life
Orion Now
Orion Group
Orion Group
Orion's century
1910s
A superstar of Finnish chemistry
It all began with Albin and woodfern
Orion’s milestones in the 1910s
1920s
A tireless promoter of children’s health
One big family
Orion’s milestones in the 1920s
1930s
Finnishness as an advertising asset
PR in the 1930s: Welcome to the Vallila plant!
Orion’s milestones in the 1930s
1940s
A miracle drug amidst the war
Orion relocated
Orion’s milestones in the 1940s
1950s
A legendary school for laboratory assistants
Finns’ favourite ointments
Orion’s milestones in the 1950s
1960s
The man behind the research
An idyllic estate
Orion’s milestones in the 1960s
1970s
How can I help you?
International horizons: rapid tests and Finnishness
Orion’s milestones in the 1970s
1980s
New address: Orionintie 1
“For manly pain” – from drugs to brands
Orion’s milestones in the 1980s
1990s
Joining forces with a competitor
An inhaler that helps asthmatics and the atmosphere
Orion’s milestones in the 1990s
2000s
The long road to market
The last hope for a heart patient
Orion’s milestones in the 2000s
2010s
Pink light to promote girls’ rights
From a mobile phone factory to a pharmaceutical plant
Orion’s milestone in the 2010s
About Orion
Management
Board of Directors
Executive management board
Orion values
Mission and strategy
Partnering and licensing
Partnering opportunities
Alliance and Partner Management Excellence
Products and Services
Prescription drugs and self-care products
Veterinary medicine
Active Pharmaceutical Ingredients
Contract manufacturing
Investors
Orion as an investment
Market reviews
Market reviews 2021
Market reviews 2020
Market reviews 2019
Market reviews 2018
Market reviews 2017
Market reviews 2016
Market reviews 2015
Market reviews 2014
Market reviews 2013
Market reviews 2012
Market reviews 2011
Market reviews 2010
Market reviews 2009
Market reviews 2008
Market reviews 2007
CEO's review
CEO Timo Lappalainen's reviews 2021
CEO Timo Lappalainen's reviews 2020
CEO Timo Lappalainen's reviews 2019
CEO Timo Lappalainen's reviews 2018
CEO Timo Lappalainen's reviews 2017
CEO Timo Lappalainen's reviews 2016
CEO Timo Lappalainen's reviews 2015
CEO Timo Lappalainen's reviews 2014
CEO Timo Lappalainen’s reviews 2013
CEO Timo Lappalainen’s reviews 2012
CEO Timo Lappalainen's reviews 2011
CEO Timo Lappalainen's reviews 2010
CEO Timo Lappalainen’s reviews 2009
CEO Timo Lappalainen’s reviews 2008
CEO's reviews 2007
Financial Information
Key figures
Quarterly figures
Credit programmes
Outlook for 2022
Outlook for 2021
Outlook for 2020
Outlook for 2019
Outlook for 2018
Outlook for 2017
Outlook for 2016
Outlook for 2015
Outlook for 2014
Outlook for 2013
Outlook for 2012
Outlook for 2011
Outlook for 2010
Outlook for 2009
Outlook for 2008
Outlook for 2007
Outlook for 2006
Basis for outlook
Accounting policies
Calculation of key figures
Financial reviews and presentations
Capital Markets Days
Financial Statements
Other events
Orion acquires Inovet's animal health business
Share information
Share capital and shares
Share-related key figures
Treasury shares
Share price
Alternative exchanges monitor
Historical share prices
Total return calculator
Dividends
Analysts
Consensus estimates
Shareholders
Major shareholders by shares
Major shareholders by votes
Ownership structure
Flagging notifications
Insider register
Conversion of shares
Changes in shareholder's contacts
Transactions of managers
Messages to shareholders
Annual General Meetings
AGM 2023
AGM 2022
AGM 2021
AGM 2020
AGM 2019
AGM 2018
AGM 2017
AGM 2016
AGM 2015
AGM 2014
AGM 2013
AGM 2012
AGM 2011
AGM 2010
AGM 2009
AGM 2008
AGM 2007
IR Calendar
Silent period
Archive
Investor Relations
CMD 2021
Media
Stock Exchange Releases
Press Releases
Managers' transactions
Subscribe to releases
Material Bank
Disclosure Policy
Corporate Governance
Corporate Governance
Corporate Governance Statement
AGM
Board of Directors
Activities and duties
Principles Concerning Diversity of the Board of Directors
Board members
Mikael Silvennoinen
Hilpi Rautelin
Kari Jussi Aho
Maziar Mike Doustdar
Ari Lehtoranta
Veli-Matti Mattila
Eija Ronkainen
Karen Lykke Sorensen
Board Committees
Nomination Committee
Authorisations of the Board of Directors
CEO and Executive Management Board
Activities and duties
Introductions of the Executive Management Board members
Liisa Hurme
Satu Ahomäki
Olli Huotari
Juhani Kankaanpää
Jari Karlson
Virve Laitinen
Niclas Lindstedt
Hao Pan
Outi Vaarala
Employee representative Jani Korhonen
Remuneration
Remuneration Report
Remuneration Policy
Share-based incentive plans
Risks and internal control
Strategic risks
Operational risks
Financial risks
Compliance risks
Insider administration
Audit
Articles of Association
Modern Slavery and Human Trafficking Statement
Contact us
Drug safety and product information
Locations and contact persons
Sites and offices
Pharmaceutical manufacturing
Sales offices and representative offices
Animal Health
Fermion
Contact persons
Invoicing addresses
Research
Research
Orion R&D
Orion's R&D Pipeline
Research areas
Research for patient well-being
Living with a diagnosis
Asthma
ALS
Prostate cancer
Breast cancer
Parkinson's disease
Alzheimer's disease
Drug development
Scientific publications
Clinical Research Privacy Statement
Human Data Research Privacy Statement
Orion Research Foundation
Information about the Research Foundation
The Administration of the Research Foundation
Instructions for grant applicant
Instructions for grant recipient
Orion Research Foundation's grants
Frequently asked questions
Contacts
Orion Research Foundation Grants for 2023: apply by 10 September 2022
Sustainability
Sustainability
Management of sustainability
Sustainability Agenda
Patient safety and reliable supply of medications
Environment
Responsibility for Orionees
Business ethics and transparency
Policies
Our approach to corporate responsibility
Code of Conduct
Human Resources Policy
EHS Policy
Quality Policy
Anti-Corruption Policy
Supplier requirements
Pharmaceutical R&D Ethics Policy
Bioethics and Animal Welfare
Using Human Tissues, GMO and Stem Cells
Ethics in the Clinical Research Phases
Ethics in the Marketing Phase
Sustainability Reports
Sustainability Report 2021
Previous reports
Patient organisation collaboration
Healthcare professional collaboration
Stories about responsibility
Raising the Bar
Careers at Orion
Careers at Orion
Open Vacancies
Applying for a job – questions and answers
Working in the pharmaceutical industry
Developing competence at Orion
Building personnel well-being
Career stories
Health Professionals
Press Releases
Select year
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2009
2008
2007
2006
1/27/2023
Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer
1/26/2023
Orion publishes Financial Statement Release for 2022 on Thursday 9 February 2023
1/4/2023
Orion and Amneal enter strategic partnership – Orion receives exclusive licence to commercialise Amneal’s generic products in Europe, Australia and New Zealand
10/27/2022
Orion Research Foundation is awarding EUR 1 million in grants and two EUR 100,000 special grants today
10/6/2022
Orion publishes Interim Report for January–September 2022 on Thursday 20 October 2022
9/5/2022
Orion recalls Devisol Salmiakki dietary supplement from consumers
8/8/2022
U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
6/28/2022
Orion publishes Half-Year Financial Report for January–June 2022 on Friday 15 July 2022
5/9/2022
The negotiations under the Act on Co-operation within Undertakings concerning Orion’s R&D have been completed – future focus on pain and oncology
5/6/2022
Orion enters into exclusive agreement with Jemincare for novel non-opioid drug candidate for the treatment of pain
5/3/2022
U.S. FDA accepts supplemental new drug application (sNDA) and grants priority review for additional indication of darolutamide
4/22/2022
Orion’s collaboration partner Bayer submits application for additional indication of darolutamide in China
4/14/2022
Orion publishes Interim Report for January–March 2022 on Thursday 28 April 2022
3/24/2022
Orion is planning to refocus its R&D – in the future focus would be on cancer and pain
3/11/2022
Orion’s collaboration partner Bayer submits application for additional indication of darolutamide in Japan
3/9/2022
Orion’s collaboration partner Bayer submits applications in the U.S. and EU for additional indication of darolutamide
2/18/2022
Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU
2/17/2022
Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with metastatic hormone-sensitive prostate cancer
1/20/2022
Orion publishes Financial Statement Release for 2021 on Thursday 10 February 2022
1/11/2022
Orion Corporation and CuraTeQ Biologics expand their biosimilar distribution agreement in Europe
11/11/2021
Orion Research Foundation grants 991,910 euros for research in 2022
10/5/2021
Orion publishes Interim Report for January–September 2021 on Wednesday 20 October 2021
8/18/2021
Orion Corporation and Alligator Bioscience announce immuno-oncology research collaboration and license agreement
8/17/2021
Orion will remain as the owner of pharmaceutical manufacturing plant in Kuopio, Finland
8/3/2021
Orion Corporation signs European wide marketing and distribution agreement with Marinus Pharmaceuticals for ganaxolone
7/12/2021
Orion recalls Multivita Forte dietary supplement from consumers
7/2/2021
Orion publishes Half-Year Financial Report for January–June 2021 on Monday 19 July 2021
6/21/2021
Orion Animal Health’s Tessie® (tasipimidine) receives positive CVMP opinion
6/9/2021
Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality Therapy
6/8/2021
Orion and the Blood Service launch collaboration to develop new CAR T-cell cancer therapy
5/26/2021
Orion’s Virtual Capital Markets Day today at 13.00 EEST – presentation material now available
5/25/2021
Orion to investigate possible sale of its pharmaceutical manufacturing plant in Kuopio, Finland
5/17/2021
Orion Animal Health’s Bonqat® (pregabalin) receives positive CVMP opinion
5/4/2021
Invitation to Orion’s Virtual Capital Markets Day on 26 May 2021
4/27/2021
Orion aims to achieve carbon neutrality by 2030
4/12/2021
Orion publishes Interim Report for January–March 2021 on Tuesday 27 April 2021
3/15/2021
Save the date – Orion’s Virtual Capital Markets Day on 26 May 2021 at 1.00 p.m. – 4.00 p.m. EEST
2/8/2021
Orion and Bayer expand development program for darolutamide in prostate cancer
1/20/2021
Orion publishes Financial Statement Release for 2020 on Tuesday 9 February 2021
1/18/2021
Orion Animal Health and Vetoquinol expand collaboration – Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania
11/10/2020
Orion invests EUR 17 million in its production plants in Turku
11/4/2020
Orion Research Foundation grants 1 014 400 euros for research in 2021
10/19/2020
Orion's statutory co-operation negotiations completed regarding the Research & Development function
10/6/2020
Orion publishes Interim Report for January-September 2020 on Wednesday 21 October 2020
9/10/2020
Orion is planning to renew its R&D strategy and organisation
9/10/2020
New England Journal of Medicine publishes final overall survival data for darolutamide showing treatment significantly extends life in men with non-metastatic prostate cancer
6/26/2020
Orion publishes Half-Year Financial Report for January-June 2020 on Friday 17 July 2020
6/26/2020
Distribution of Zoetis’ products in Sweden, Denmark and Norway by Orion to end after 2020
6/4/2020
Orion is developing an immuno-oncology (IO) drug discovery platform in the national research and innovation consortium Cancer IO
5/20/2020
Sales of darolutamide started in the EU and Japan – Orion receives total of EUR 28 million milestones
5/14/2020
New ARAMIS Phase III data to be presented at ASCO 2020: Nubeqa® (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancer
4/14/2020
Orion publishes Interim Report for January-March 2020 on Tuesday 28 April 2020
3/30/2020
Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer
2/13/2020
Tero Närvänen is appointed Orion's new Vice President Quality Management as of 1 May 2020
1/31/2020
Positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer
1/30/2020
Darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer
1/23/2020
Marketing authorization granted for darolutamide in Japan
1/22/2020
Orion publishes Financial Statement Release for 2019 on 5 February 2020
12/30/2019
Lotus to distribute Orion’s Stalevo® and Comtan® drugs in parts of Asia
12/9/2019
Orion presented data on oral levosimendan at the 30th International Symposium on ALS/MND
12/2/2019
Orion to present four posters on oral levosimendan in patients with ALS at the 30th International Symposium on ALS/MND
11/4/2019
Orion Research Foundation grants 902 000 euros for research in 2020
10/7/2019
Publishing of Orion Corporation's Interim Report for January-September 2019 on 23 October 2019
9/10/2019
Orion recalls Melatoniini Orion 1 mg Spray 20 ml oral spray from consumers
8/7/2019
Sales of darolutamide started in the USA – Orion receives EUR 45 million milestone
7/31/2019
U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC)
7/15/2019
Orion completes enrollment in the REFALS Phase 3 trial studying the effect of oral Levosimendan in patients with amyotrophic lateral sclerosis (ALS)
6/27/2019
Publishing of Orion Corporation's Half Year Report for January-June 2019 on 17 July 2019
5/31/2019
2019 American Society of Clinical Oncology (ASCO) Annual Meeting - Darolutamide data presented
4/29/2019
U.S. FDA accepts New Drug Application for review and grants Priority Review for darolutamide
4/11/2019
Fire at Orion’s manufacturing plant in Turku
4/11/2019
Publishing of Orion Corporation's Interim Report for January-March 2019 on 25 April 2019
3/27/2019
Invitation to Orion's Capital Markets Day in Helsinki on Wednesday 22 May 2019
3/8/2019
Darolutamide submitted for European marketing authorization
3/5/2019
Darolutamide submitted for marketing authorization in Japan
2/27/2019
The rolling submission to FDA for darolutamide in the U.S. completed
2/14/2019
Orion's and Bayer's darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the ARAMIS trial
2/11/2019
Orion and Propeller Health partner to bring new digital medicines to people with asthma and COPD
2/5/2019
Orion and Bayer jointly present new data in prostate cancer from the Darolutamide ARAMIS -study
2/4/2019
Orion intents to start an open label extension study to the REFALS phase 3 trial studying the effect of oral levosimendan in patients with ALS
1/23/2019
Publishing of Orion Corporation's Financial Statement Release for 2018 on 6 February 2019
1/4/2019
Orion Corporation and Fifth Corner Inc join forces to research solutions for improving the quality of life of prostate cancer patients
12/4/2018
Orion acquires sales and distribution rights for certain European Countries for Parkinson's disease drug Stalevo
11/1/2018
Orion Research Foundation grants million euros for research in 2019
10/24/2018
Orion and Amgen to collaborate on the commercialisation of AMGEVITA® (biosimilar adalimumab) in Finland
10/10/2018
Publishing of Orion Corporation's Interim Report for January-September 2018 on 24 October 2018
9/17/2018
Creation of novel medicines and better patient care for the future in an ecosystem
9/10/2018
Johanna Ivaska has been appointed Head & Vice President of Oncology Research in Orion Corporation
7/6/2018
Orion has started a Phase III trial to develop a drug for ALS - The patient recruitment has begun
7/5/2018
Publishing of Orion Corporation's Half-Year Financial Report for January-June 2018 on 18 July 2018
6/14/2018
Fermion's new plant operational in Hanko - nearly 100% of production is exported
6/13/2018
Orion to join John Nurminen Foundation's Clean Baltic Sea projects as a new main partner
4/30/2018
Orion has completed the sale of Orion Diagnostica business division
4/10/2018
Publishing of Orion Corporation's Interim Report for January-March 2018 on 24 April 2018
4/3/2018
Status update of the Phase III ARAMIS clinical trial with darolutamide in patients with non-metastatic castration-resistant prostate cancer
3/19/2018
Orion has received positive conclusions for the salmeterol-fluticasone Easyhaler® combination under the EU's decentralized procedures
2/28/2018
Orion's statutory co-operation negotiations completed
1/24/2018
Publishing of Orion Corporation's Financial Statement Release for 2017 on 7 February 2018
1/4/2018
Orion to renew operating model of its laboratories
11/7/2017
Professor Heikki Joensuu has been appointed Vice President of Therapy area Oncology, R&D in Orion Corporation
10/12/2017
Publishing of Orion Corporation's Interim Report for January-September 2017 on 26 October 2017
10/5/2017
Orion receives Lean Prize 2016
9/22/2017
Orion Pharma scientists led research group wins award for study paper on dexmedetomidine oromucosal gel for noise anxiety in dogs
7/5/2017
Publishing of Orion Corporation's Half-Yearly Report for January-June 2017 on 19 July 2017
6/2/2017
Orion Diagnostica's co-operation negotiations in Oulu completed
5/18/2017
Orion Capital Markets Day 2017 today 18 May 2017 in Helsinki
5/16/2017
Välittämö100 Web service enables you to donate to carers and their families
4/6/2017
Orion Diagnostica initiates co-operation negotiations concerning 14 persons in Oulu
3/16/2017
Invitation to Orion's Capital Markets Day in Helsinki on May 18, 2017
2/10/2017
Orion Research Foundation grants EUR 1 million for research
1/27/2017
Reijo Salonen, Senior Vice President, Pharmaceutical R&D, is CTO of the Year 2017
12/21/2016
Orion is planning to apply for a marketing authorisation for combined salmeterol-fluticasone formulation of the Easyhaler® product family
12/14/2016
Orion and University of Wisconsin-Madison will start strategic collaboration
9/2/2016
Orion Corporation and Menarini Group collaborate on budesonide-formoterol Easyhaler® combination product for asthma and COPD
6/22/2016
Orion Corporation and Asahi Kasei enter into global strategic collaboration
3/11/2016
Fermion invests in a new production facility in Hanko
3/7/2016
The German Center for Neurodegenerative Diseases and Orion Corporation start strategic collaboration
12/3/2015
Orion has developed Sileo® product to alleviate noise anxiety in dogs - marketing authorisation in the EU area
12/2/2015
Controlling medication risks with a new drug category - Finns want simple pain relief
11/25/2015
No foreign capsules detected in packages of Orion's Burana-Caps
11/24/2015
Orion recalls Burana-Caps 400 mg capsules from pharmacies and consumers as a precaution
8/13/2015
Kaisa Tarkkanen has been appointed as President of Orion Diagnostica Oy as of 1 October 2015
4/13/2015
Invitation to Orion's Capital Markets Day on 26 May 2015
3/26/2015
Orion signs cooperation agreement with HUCH Comprehensive Cancer Center
3/3/2015
Save the Date: Orion Corporation's Capital Market Day in Helsinki on 26 May 2015
2/5/2015
Orion Pharma Animal Health and Vetoquinol enter into distribution collaboration as of 1 January 2015
11/18/2014
Arto Toivonen has been appointed as President of Fermion Oy as of 1 January 2015
10/2/2014
Orion is campaigning in pink for girls
4/14/2014
ODM-201 offers a new therapeutic option for the treatment of prostate cancer
3/21/2014
Orion's pharmaceutical plant opens in Salo - investment will create over 100 jobs
2/3/2014
The androgen receptor inhibitor ODM-201 - New insights in the treatment of prostate cancer
12/17/2013
Orion Diagnostica Oy and Eurofins Medigenomix enter into a license agreement on Orion Diagnostica Oy's proprietary SIBA® technology
10/22/2013
Orion licenses the levosimendan injection rights in the USA and Canada to Phyxius
9/28/2013
Encouraging results from a clinical Phase II trial of ODM-201 for advanced prostate cancer (ARADES Trial)
3/21/2013
Orion Corporation presented promising Phase II data for new Parkinson's disease drug at AAN Annual Meeting
3/21/2013
Orion Corporation presented promising Phase II data for new Alzheimer's disease drug at AAN Annual Meeting
3/12/2013
Orion Corporation and Gedeon Richter signed novel CNS R&D collaboration agreement
2/15/2013
Promising preclinical and Phase I data of a new generation androgen receptor (AR) inhibitor, ODM- 201, presented at ASCO GU 2013 symposium
10/30/2012
Results of independent analyses show that Orion's DeviSol preparation meets its requirements
10/25/2012
Orion planning new packaging and logistics centre - new jobs in Salo
10/23/2012
Orion receives positive Phase II study results of a new levodopa product for Parkinson's disease
9/30/2012
Phase I/II ARADES trial of a new generation anti-androgen, ODM- 201, presented at ESMO 2012 congress
9/21/2012
Researcher Hannes Lohi receives an award worth EUR 75,000 - Canine genetic research also helps understand human diseases
3/22/2012
Orion's MIDEX and PRODEX results published in JAMA
12/21/2011
Production restarts at Orion's manufacturing plant in Turku after the fire in November
11/22/2011
Fire stops production at Orion's manufacturing plant in Turku
10/5/2011
Orion Corporation introduces new intensive care sedative Dexdor®
8/4/2011
Orion Corporation and Nycomed to collaborate on Easyhaler® for asthma and COPD
1/28/2011
Orion Corporation and Endo Pharmaceuticals enter into novel R&D collaboration
6/15/2009
Reijo Salonen receives the title of Professor
6/25/2008
Orion's marketing rights for Paclical® Vet (paclitaxel) expanded European-wide
5/30/2008
Orion receives rights for incontinence drug Kentera® from Recordati
4/4/2008
Orion receives European rights from Indevus for Vantas®, for prostate cancer
12/28/2007
Orion-Farmos Tutkimussäätiö jakaa 50-vuotisjuhlansa kunniaksi tutkimukseen 0,65 miljoonaa euroa
5/29/2007
Orion introduces a medicine for treating obese dogs
10/31/2006
New evidence demonstrates early use of Stalevo improves quality of life and may provide long-term benefits in patients with Parkinson's disease
10/10/2006
Management change in Orion's Communications
Orion's century
1910s
A superstar of Finnish chemistry
It all began with Albin and woodfern
Orion’s milestones in the 1910s
1920s
A tireless promoter of children’s health
One big family
Orion’s milestones in the 1920s
1930s
Finnishness as an advertising asset
PR in the 1930s: Welcome to the Vallila plant!
Orion’s milestones in the 1930s
1940s
A miracle drug amidst the war
Orion relocated
Orion’s milestones in the 1940s
1950s
A legendary school for laboratory assistants
Finns’ favourite ointments
Orion’s milestones in the 1950s
1960s
The man behind the research
An idyllic estate
Orion’s milestones in the 1960s
1970s
How can I help you?
International horizons: rapid tests and Finnishness
Orion’s milestones in the 1970s
1980s
New address: Orionintie 1
“For manly pain” – from drugs to brands
Orion’s milestones in the 1980s
1990s
Joining forces with a competitor
An inhaler that helps asthmatics and the atmosphere
Orion’s milestones in the 1990s
2000s
The long road to market
The last hope for a heart patient
Orion’s milestones in the 2000s
2010s
Pink light to promote girls’ rights
From a mobile phone factory to a pharmaceutical plant
Orion’s milestone in the 2010s
About Orion
Management
Board of Directors
Executive management board
Orion values
Mission and strategy
Partnering and licensing
Partnering opportunities
Alliance and Partner Management Excellence
Products and Services
Prescription drugs and self-care products
Veterinary medicine
Active Pharmaceutical Ingredients
Contract manufacturing
Investors
Orion as an investment
Market reviews
Market reviews 2021
Market reviews 2020
Market reviews 2019
Market reviews 2018
Market reviews 2017
Market reviews 2016
Market reviews 2015
Market reviews 2014
Market reviews 2013
Market reviews 2012
Market reviews 2011
Market reviews 2010
Market reviews 2009
Market reviews 2008
Market reviews 2007
CEO's review
CEO Timo Lappalainen's reviews 2021
CEO Timo Lappalainen's reviews 2020
CEO Timo Lappalainen's reviews 2019
CEO Timo Lappalainen's reviews 2018
CEO Timo Lappalainen's reviews 2017
CEO Timo Lappalainen's reviews 2016
CEO Timo Lappalainen's reviews 2015
CEO Timo Lappalainen's reviews 2014
CEO Timo Lappalainen’s reviews 2013
CEO Timo Lappalainen’s reviews 2012
CEO Timo Lappalainen's reviews 2011
CEO Timo Lappalainen's reviews 2010
CEO Timo Lappalainen’s reviews 2009
CEO Timo Lappalainen’s reviews 2008
CEO's reviews 2007
Financial Information
Key figures
Quarterly figures
Credit programmes
Outlook for 2022
Outlook for 2021
Outlook for 2020
Outlook for 2019
Outlook for 2018
Outlook for 2017
Outlook for 2016
Outlook for 2015
Outlook for 2014
Outlook for 2013
Outlook for 2012
Outlook for 2011
Outlook for 2010
Outlook for 2009
Outlook for 2008
Outlook for 2007
Outlook for 2006
Basis for outlook
Accounting policies
Calculation of key figures
Financial reviews and presentations
Capital Markets Days
Financial Statements
Other events
Orion acquires Inovet's animal health business
Share information
Share capital and shares
Share-related key figures
Treasury shares
Share price
Alternative exchanges monitor
Historical share prices
Total return calculator
Dividends
Analysts
Consensus estimates
Shareholders
Major shareholders by shares
Major shareholders by votes
Ownership structure
Flagging notifications
Insider register
Conversion of shares
Changes in shareholder's contacts
Transactions of managers
Messages to shareholders
Annual General Meetings
AGM 2023
AGM 2022
AGM 2021
AGM 2020
AGM 2019
AGM 2018
AGM 2017
AGM 2016
AGM 2015
AGM 2014
AGM 2013
AGM 2012
AGM 2011
AGM 2010
AGM 2009
AGM 2008
AGM 2007
IR Calendar
Silent period
Archive
Investor Relations
CMD 2021
Media
Stock Exchange Releases
Press Releases
Managers' transactions
Subscribe to releases
Material Bank
Disclosure Policy
Corporate Governance
Corporate Governance
Corporate Governance Statement
AGM
Board of Directors
Activities and duties
Principles Concerning Diversity of the Board of Directors
Board members
Mikael Silvennoinen
Hilpi Rautelin
Kari Jussi Aho
Maziar Mike Doustdar
Ari Lehtoranta
Veli-Matti Mattila
Eija Ronkainen
Karen Lykke Sorensen
Board Committees
Nomination Committee
Authorisations of the Board of Directors
CEO and Executive Management Board
Activities and duties
Introductions of the Executive Management Board members
Liisa Hurme
Satu Ahomäki
Olli Huotari
Juhani Kankaanpää
Jari Karlson
Virve Laitinen
Niclas Lindstedt
Hao Pan
Outi Vaarala
Employee representative Jani Korhonen
Remuneration
Remuneration Report
Remuneration Policy
Share-based incentive plans
Risks and internal control
Strategic risks
Operational risks
Financial risks
Compliance risks
Insider administration
Audit
Articles of Association
Modern Slavery and Human Trafficking Statement
Contact us
Drug safety and product information
Locations and contact persons
Sites and offices
Pharmaceutical manufacturing
Sales offices and representative offices
Animal Health
Fermion
Contact persons
Invoicing addresses